TROPION-Lung01 Study Design and Baseline demographics slide image

TROPION-Lung01 Study Design and Baseline demographics

The BEGONIA Study (NCT03742102) Rationale Immune checkpoint inhibitors + chemotherapy is the standard of care for patients with PD-L1 positive a/mTNBC; still, most progress within a year (median PFS-9-10 months) 1.2 BEGONIA is evaluating combinations of durvalumab (D), an anti-PD-L1 antibody, with other novel therapies in first-line a/mTNBC Dato-DXd is a TROP2-directed ADC with a TOPO I inhibitor payload and a tumour- selective cleavable linker³ At median 7.2 months follow-up, ORR was 74% for patients treated with Dato-DXd + D in BEGONIA+ Eligibility criteria Females aged ≥18 years • Unresectable a/m TNBC + No prior treatment for Stage IV TNBC ⚫ ≥12 months since prior taxane therapy • ECOG PS 0-1 ♦ Adequate organ function ◆ Measurable disease per RECIST v1.1 ◆ No prior treatment with checkpoint inhibitor ◆ No prior treatment with TOPO I-based ADC* Study Design Treatment arms Arm 1: Paclitaxel (P) + D (N=20) Arm 2: Capivasertib + P + D (N=30) Part 1 Part 2 expansion Arm 5: Oleclumab +P + D (N=30) Arm 6: T-DXd + D (N=30) Safety run-in (up to Simon 6 patients) Arm 7: Dato-DXd 6 mg/kg + D 1120 mg (N=30) Q3W until PD 2-stage futility analysis for Part 2 expansion* Arm 8: Dato-DXd + D. PD-L1 positive (N=30) 1° endpoint: Safety and tolerability 2° endpoints: ORR, PFS, DOR, OS Arms that meet expansion criteria enrol additional 27 patients 1° endpoint: ORR 2° endpoints: PFS, DoR, PFS6, OS We report updated results with longer follow-up for patients from Parts 1 and 2 treated with Dato-DXd + D in BEGONIA Arm 7 *ADC-cohort-specific criteria. "Currently enrolling; a safety run-in will not accur for this arm as Dato-DXd+ D was already evaluated and found to be tolerable with no dose-limiting toxicities reported. "Novel treatment combinations may enter Part 2 expansion if confirmed ORR is at least 57%. 1. Cortes J. et al. Lancet. 2020:396/10265):1817-1828. 2. Emens LA, et al. J Natl Cancer Inst. 2021;113(8):1005-1016. 3. Bardia A. et al. Presented at SABOS 2022. P6-10-03. 4. Schmid P, et al. Presented at SABCS 2022. PD11-08. ADC, antibody-drug conjugate; almTNBC, advanced metastatic triple-negative breast cancer; Dato-DXd, datopolamab deruxtecan; DoR, duration of response; D, durvalumab; ECOG PS, Eastem Cooperative Oncology Group performance status; ORR, objective response rate; OS, overall survival; PD. progressive disease; PD-L1. programmed death ligand-1; PFS progression-free survival; PFS6. progression-free survival at 6 months; 03W, every 3 weeks: RECIST, Response Evaluation Criteria In Solid Tumors; T-DXd, trastuzumab deruxtecan; TOPO I, topoisomerase I; TROP2, trophoblast cell- surface antigen 2. Daiichi-Sankyo 37
View entire presentation